Keyi Jia

1.1k total citations · 1 hit paper
27 papers, 730 citations indexed

About

Keyi Jia is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Keyi Jia has authored 27 papers receiving a total of 730 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 7 papers in Immunology. Recurrent topics in Keyi Jia's work include Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Keyi Jia is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Treatments and Mutations (9 papers). Keyi Jia collaborates with scholars based in China, Poland and United States. Keyi Jia's co-authors include Yayi He, Sha Zhao, Caicun Zhou, Minlin Jiang, Xiaoshen Zhang, Yu Liu, Hao Wang, Lei Wang, Juan Deng and Wei Li and has published in prestigious journals such as Science Advances, Genomics and Cancer Science.

In The Last Decade

Keyi Jia

27 papers receiving 724 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

2021 203 citations Minlin Jiang, Keyi Jia et al. Acta Pharmaceutica Sinica B profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keyi Jia China	13	441	276	234	196	111	27	730
Brian Belmontes United States	13	421 1.0×	322 1.2×	169 0.7×	203 1.0×	84 0.8×	22	757
Christian Britschgi Switzerland	17	413 0.9×	272 1.0×	145 0.6×	289 1.5×	101 0.9×	59	770
Yuzi Zhang China	14	568 1.3×	213 0.8×	176 0.8×	187 1.0×	188 1.7×	45	797
Rilan Bai China	13	567 1.3×	240 0.9×	306 1.3×	247 1.3×	171 1.5×	36	920
Virginia Picasso Italy	12	400 0.9×	314 1.1×	197 0.8×	101 0.5×	56 0.5×	16	661
Naoyuki Okabe Japan	15	392 0.9×	212 0.8×	173 0.7×	255 1.3×	197 1.8×	56	706
Luis Paz Ares Spain	7	462 1.0×	188 0.7×	154 0.7×	262 1.3×	99 0.9×	10	665
Sofia Genta Canada	12	434 1.0×	289 1.0×	170 0.7×	139 0.7×	135 1.2×	36	742
Jacob J. Orme United States	14	227 0.5×	241 0.9×	251 1.1×	201 1.0×	112 1.0×	74	744
Antonio Cusmai Italy	11	292 0.7×	197 0.7×	138 0.6×	124 0.6×	109 1.0×	28	577

Countries citing papers authored by Keyi Jia

Since Specialization

Citations

This map shows the geographic impact of Keyi Jia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyi Jia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyi Jia more than expected).

Fields of papers citing papers by Keyi Jia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyi Jia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyi Jia. The network helps show where Keyi Jia may publish in the future.

Co-authorship network of co-authors of Keyi Jia

This figure shows the co-authorship network connecting the top 25 collaborators of Keyi Jia. A scholar is included among the top collaborators of Keyi Jia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyi Jia. Keyi Jia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ren, Shengxiang, Yaqi Chen, Anyi Liu, et al.. (2023). PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance. Science Advances. 9(21). eade4186–eade4186. 40 indexed citations

Jia, Keyi, Bin Chen, Jia Yu, et al.. (2022). Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report. Annals of Translational Medicine. 10(6). 386–386. 9 indexed citations

Jiang, Minlin, Keyi Jia, Lei Wang, et al.. (2021). Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharmaceutica Sinica B. 11(10). 2983–2994. 203 indexed citations breakdown →

Mao, Shiqi, Fei Zhou, Yiwei Liu, et al.. (2021). ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunology Immunotherapy. 71(1). 219–228. 7 indexed citations

Wu, Fengying, Xuefei Li, Chao Zhao, et al.. (2021). Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Frontiers in Oncology. 11. 639947–639947. 29 indexed citations

Yu, Xiaofei, Zhengwei Dong, Wanying Wang, et al.. (2021). Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer. Cancer Management and Research. Volume 13. 3981–3990. 4 indexed citations

Zhang, Xuehan, Haoyue Guo, Yu Liu, et al.. (2021). Research progress on the molecular mechanisms of hepatic metastasis in lung cancer: a narrative review. Annals of Palliative Medicine. 10(4). 4806–4822. 12 indexed citations

Wang, Boyuan, Haoyue Guo, Yü Liu, et al.. (2021). Collection on reports of molecules linked to epithelial-mesenchymal transition in the process of treating metastasizing cancer: a narrative review. Annals of Translational Medicine. 9(11). 946–946. 6 indexed citations

Liu, Yiwei, Wanying Wang, Fengying Wu, et al.. (2021). High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations. Translational Lung Cancer Research. 10(3). 1512–1524. 20 indexed citations

10.

Li, Wěi, Hao Wang, Bin Chen, et al.. (2020). Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review. Translational Lung Cancer Research. 9(2). 379–388. 6 indexed citations

11.

Deng, Juan, Xiaoxia Chen, Yu Liu, et al.. (2020). Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction. Annals of Translational Medicine. 8(14). 889–889. 3 indexed citations

12.

Sun, Chenglong, Wei Zhang, Yü Liu, et al.. (2020). <p>Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer</p>. OncoTargets and Therapy. Volume 13. 6475–6483. 32 indexed citations

13.

Chen, Shanhao, Shengyu Wu, Ping Zhang, et al.. (2020). CD39: the potential target in small cell lung cancer. Translational Lung Cancer Research. 9(4). 1483–1495. 15 indexed citations

14.

Jiang, Minlin, Keyi Jia, Lei Wang, et al.. (2020). Alterations of DNA damage repair in cancer: from mechanisms to applications. Annals of Translational Medicine. 8(24). 1685–1685. 63 indexed citations

15.

He, Yayi, Keyi Jia, Rafał Dziadziuszko, et al.. (2019). Galectin-9 in non-small cell lung cancer. Lung Cancer. 136. 80–85. 36 indexed citations

16.

Wang, Hao, Sha Zhao, Xiaoshen Zhang, et al.. (2019). <p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>. OncoTargets and Therapy. Volume 12. 7281–7288. 10 indexed citations

17.

Gao, Guanghui, Keyi Jia, Sha Zhao, et al.. (2019). Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer. Translational Lung Cancer Research. 8(6). 920–928. 2 indexed citations

18.

Zhang, Xiaoshen, Yayi He, Keyi Jia, et al.. (2019). Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. Translational Lung Cancer Research. 8(5). 559–574. 5 indexed citations

19.

He, Yayi, Xiaoshen Zhang, Keyi Jia, et al.. (2019). OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. Translational Lung Cancer Research. 8(4). 352–366. 38 indexed citations

20.

Jia, Keyi, Yayi He, Rafał Dziadziuszko, et al.. (2019). T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. Translational Lung Cancer Research. 8(6). 895–906. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact